Amneal Pharmaceuticals, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This 10-K reports annual results; it does not provide standalone fourth-quarter financial results. The company develops, manufactures, markets and distributes generic, injectable, biosimilar and specialty medicines, as well as government-focused pharmaceutical products through AvKARE. On November 7, 2023, it simplified its corporate structure; the public company thereafter owned 100% of Amneal Pharmaceuticals, LLC.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net revenue | $2.394 billion | $2.212 billion |
| Gross profit / gross margin | $820.6 million / 34.3% | $784.7 million / 35.5% |
| Operating income (loss) | $204.4 million | $(94.9) million |
| Net loss | $(48.7) million | $(254.8) million |
| Net loss attributable to Amneal; diluted EPS | $(84.0) million; $(0.48) | $(130.0) million; $(0.86) |
| Cash from operating activities | $345.6 million | $65.1 million |
| Cash used in investing activities | $69.2 million | $174.3 million |
| Cash used in financing activities | $212.6 million | $106.6 million |
Revenue increased 8.2%, while gross margin contracted 1.2 percentage points. Operating income improved substantially, mainly against the prior-year $269.9 million net charge for legal matters. The company still reported a consolidated net loss; the difference between consolidated net loss and loss attributable to Amneal reflects non-controlling interests.
At year-end, cash and cash equivalents were $91.5 million, with $7.6 million of restricted cash. Total borrowings were approximately $2.72 billion, including $2.544 billion of term loans and $179 million drawn on the revolving facility. The company reported $253.2 million of additional revolving capacity. Net accounts receivable was $613.7 million and inventory was $581.4 million. Total stockholders’ equity was $20.0 million.
Segments and changes versus prior year
| Segment | FY2023 revenue | Change | FY2023 operating income |
|---|---|---|---|
| Generics | $1.471 billion | +2.7% | $276.2 million |
| Specialty | $390.5 million | +4.4% | $65.3 million |
| AvKARE | $531.7 million | +30.9% | $31.5 million |
- Generics growth reflected new launches, including biosimilars, partly offset by price erosion. Revenue included a non-recurring $21 million customer order. Generics operating income increased 23.2%.
- AvKARE growth came from distribution and government channels, including new products; improved channel mix lifted gross margin to 16.3% from 14.0%.
- Specialty revenue growth reflected endocrinology gains. Its operating income fell 10.0%, as higher cost of goods sold and product impairment more than offset revenue growth.
Outlook, management commentary and key risks
- Management said available cash, operating cash generation and borrowing capacity should be sufficient to fund planned operations and obligations for the next 12 months, subject to business and market conditions. Planned 2024 capital expenditures are approximately $60–$70 million.
- Management estimated inflation increased costs by approximately $15 million in 2023 and expects a $15–$20 million impact in 2024. These are cost estimates, not earnings guidance; the filing provides no clear full-year 2024 revenue or earnings forecast.
- Debt refinancing in November 2023 extended $2.35 billion of term-loan borrowings to May 2028, leaving $192.0 million due in May 2025. Year-end rates were approximately 10.9% on the 2028 term loan and 9.0% on the 2025 term loan. The filing estimates 2024 interest payments of $274.6 million on the term loans, excluding the swap and revolving borrowings, and $58.8 million of 2024 principal payments on the 2028 loan.
- Unusual items included $66.9 million of intangible-asset impairment charges, including $36.1 million primarily related to LYVISPAH and $30.8 million for two in-process R&D assets after adverse clinical-trial results. The company also recorded a $40.8 million refinancing loss. These items affected comparability.
- IPX203, a Parkinson’s disease candidate, received an FDA complete response letter in June 2023 over additional information needed on carbidopa safety bridging; the FDA did not identify efficacy or manufacturing issues. Following a requested QT study, the company resubmitted the application on February 7, 2024. Approval and timing remain uncertain.
- Customer concentration is significant: four largest customers represented approximately 70% of 2023 revenue, and the company has no long-term agreements guaranteeing future purchases. Generic-drug price erosion, competition, supply interruptions and reliance on third parties also pose material risks.
- Legal exposure includes opioid litigation and ongoing generic-drug pricing antitrust and government investigations. The company paid $52.4 million in January 2024 to complete the Opana ER antitrust settlement. Outcomes and potential losses in several other matters are uncertain or not estimable.
- The tax receivable agreement requires payment of 75% of certain realized tax benefits. A contingent liability of $185.2 million was unrecorded at year-end because realization of the related tax assets was not considered more likely than not; the recorded TRA liability was $3.7 million.
- The company reported effective disclosure controls and internal control over financial reporting, and its auditor issued unqualified opinions on the financial statements and internal controls.
Most important facts for investors to verify
- Whether operating cash flow remains strong after the favorable 2023 collections timing, and how working capital and inventory develop.
- Debt service capacity, refinancing options for the $192.0 million May 2025 maturity, variable-rate exposure and remaining revolver availability.
- Whether revenue growth persists after the non-recurring $21 million Generics order, and whether generic price erosion or customer concentration worsens.
- FDA progress and potential commercial prospects for IPX203, along with the performance of biosimilars, ONGENTYS and other launches.
- Further impairment risk and the eventual cash and earnings effects of litigation, the TRA and other contingencies.